News

The company claims that MLN4924 is the first small molecule inhibitor that specifically targets this class of enzyme to be studied clinically, and is currently being studied in

China Sky One Medical has completed this first phase of construction in December 2009. The company’s two new six-story buildings cost approximately $13m and will accommodate administration, research

Celgene has acquired Gloucester for $340m in cash plus up to an additional $300m payable upon achievement of certain future regulatory milestones. The transaction brings to Celgene Istodax

Following receipt of the notice from the FDA that Impax’s ANDA had been accepted for filing, Impax has notified the New Drug Application holder and patent owners of

The company claims that Bacitracin Ophthalmic ointment, USP is the first product transfer to be completed. It is anticipated that the transfer of Erythromycin Ophthalmic ointment is expected

Currently, over 143 patients are enrolled in the CTCL study. The study is a multinational, non-randomised, open-label, single-arm trial, evaluating 200mg once-daily oral Forodesine treatment. Reportedly, the study

The result was published in the January issue of Mayo Clinic Women’s HealthSource. It also posts safety concerns and the maximum dose to be taken. The reported adverse

Tarceva is a once-a-day pill that targets the EGFR pathway. It is designed to inhibit the tyrosine kinase activity of the EGFR signaling pathway inside the cancer cell.

The original SCD-HeFT study has proved the effectiveness of ICD therapy over placebo or Amiodarone (a medication used to treat irregular heartbeats) for a specific population of patients.